financetom
Business
financetom
/
Business
/
Blue Origin targets late spring for next New Glenn launch after FAA probe
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Blue Origin targets late spring for next New Glenn launch after FAA probe
Mar 31, 2025 11:35 AM

WASHINGTON (Reuters) -Jeff Bezos' Blue Origin said on Monday it is targeting "late spring" for the second launch of its giant New Glenn rocket, as the U.S. FAA closed an investigation into the rocket's landing failure that followed an otherwise successful debut mission in January.

The two-stage New Glenn rocket launched for the first time in January after years of development delays and successfully placed a satellite in orbit. But afterward, the rocket's reusable first-stage booster failed in its landing attempt on a vessel in the Atlantic Ocean, triggering an FAA probe.

Blue Origin said in a statement on Monday that the landing failure was "due to our three BE-4 engines not re-igniting properly," without providing further technical detail.

The company said its investigative report into the landing failure "identified seven corrective actions, focusing on propellant management and engine bleed control improvements, which we're already addressing."

"We expect to return to flight in late spring and will attempt to land the booster again," Blue Origin said.

A statement on Monday from the FAA, which oversees U.S. launch safety matters, confirmed the closing of its review of Blue Origin's technical probe, saying, "The FAA will verify that Blue Origin implements corrective actions prior to the launch of the New Glenn-2 mission."

Blue Origin's New Glenn debut was the company's first step into Earth's orbit, a pivotal moment for Bezos' space ambitions as he tries to compete with Elon Musk's SpaceX on multiple fronts - from satellite launches to moon landings to lucrative Pentagon contracts for secretive military space operations.

Weeks after New Glenn's first launch, Blue Origin CEO Dave Limp laid off 10 percent of the company's 14,000 employees in a move to cut costs and shift New Glenn unit's focus on rocket production and a swift launch cadence.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
GXO Logistics Strikes Deliveries Partnership With The Perfume Shop
GXO Logistics Strikes Deliveries Partnership With The Perfume Shop
Jan 15, 2025
04:49 AM EST, 01/15/2025 (MT Newswires) -- GXO Logistics ( GXO ) said Wednesday it has been retained by The Perfume Shop, a UK fragrance retailer, to provide weekly deliveries to stores through its shared transport network. Financial terms were not disclosed. Shares of GXO gained 3% in premarket activity. ...
Celanese Advises Shareholders to Decline TRC Capital's Mini-Tender Offer
Celanese Advises Shareholders to Decline TRC Capital's Mini-Tender Offer
Jan 15, 2025
05:03 AM EST, 01/15/2025 (MT Newswires) -- Celanese (CE) said late Tuesday it learned of an unsolicited mini-tender offer from TRC Capital to buy up to 1.5 million shares at $65.50 each in cash. The company said the offer is lower than its Dec. 13 closing price of $68.58. Celanese does not approve of the offer and recommends shareholders decline...
Space startup funding set for boost from US-China rivalry in 2025, report says
Space startup funding set for boost from US-China rivalry in 2025, report says
Jan 15, 2025
Jan 15 (Reuters) - Funding in the space industry is set to receive a boost this year from growing U.S.-China tensions, after startups in the sector clocked $8.6 billion in investments in 2024, according to a report by investment firm Seraphim Space. China has been increasing its efforts to go toe-to-toe with Western countries in sectors such as satellite production...
Biopharma industry eyes 2025 bounceback, grapples with uncertainty over Trump return
Biopharma industry eyes 2025 bounceback, grapples with uncertainty over Trump return
Jan 15, 2025
SAN FRANCISCO (Reuters) - The biopharmaceutical industry is aiming for a 2025 reversal of last year's slump in investor returns but remains wary over what President-elect Donald Trump's priorities might be on hot button issues such as drug pricing reforms and vaccines. The pharma industry faced its biggest regulatory change in decades with the Biden Administration's Inflation Reduction Act of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved